MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » UPDATE: Zoll gets a regulatory nod for the new LifeVest

UPDATE: Zoll gets a regulatory nod for the new LifeVest

By

Zoll Medical Corp. got the green light from the Food & Drug Administration to market another generation of the company’s LifeVest product.

Officials said the LifeVest 4000 series is the fourth generation of a wearable defibrillator the Chelmsford-based company first introduced in 2002. The device monitors for arrhythmic conditions and provides an emergency defibrillation to patients who have suffered a major heart attack and may require further surgical intervention, such as having an implantable defibrillator procedure.

Zoll CEO Richard Packer told MassDevice that the $1.8 billion potential market for the product and lack of competition makes the LifeVest one of the company’s most promising product lines for the future.

“I think the LifeVest (by itself) has the potential to be as big a part of Zoll as the rest of Zoll is today,” he said. “I think it will be a very significant part of the company.”

Recent sales numbers seem to back up Packer’s claim. According to the company’s latest quarterly earnings report LifeVest revenues increased 58 percent to $11.9 million during the three month period ended June 30, compared to $7.5 million for the same period last year.

And Zoll is throwing its muscle behind the LifeVest to increase adoption.

Packer said the company is in the process of more than doubling the LifeVest sales force. At the end of the quarter, Packer said the company had about 65 salespeople in the field and that he expects the company will hire an additional 20 by the end of 2009, with a goal of having 120 sales people in the field selling the LifeVest.

He added that the latest generation of the LifeVest, which has some upgraded electronics and is “easier to interact with,” would work interchangeably with earlier generations on the market and that there would be no need to offer rebates or other sweeteners to get customers to upgrade. He explained that currently patients rent the LifeVest and it is considered a piece of durable medical equipment.

There are more than 17,000 patients who have been fitted with the device to date, according to the company.

In case you missed it

RSS From Medical Design & Outsourcing

  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]

Leave a Reply